Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Non-Current Deffered Revenue (2016 - 2018)

Viking Therapeutics (VKTX) has disclosed Non-Current Deffered Revenue for 4 consecutive years, with $12000.0 as the latest value for Q4 2018.

  • Quarterly Non-Current Deffered Revenue changed N/A to $12000.0 in Q4 2018 from the year-ago period, while the trailing twelve-month figure was $12000.0 through Dec 2018, changed N/A year-over-year, with the annual reading at $12000.0 for FY2018, N/A changed from the prior year.
  • Non-Current Deffered Revenue hit $12000.0 in Q4 2018 for Viking Therapeutics, up from $6054.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $31239.0 in Q4 2015 to a low of $6054.0 in Q2 2017.
  • Historically, Non-Current Deffered Revenue has averaged $18706.3 across 4 years, with a median of $19149.0 in 2015.
  • Biggest five-year swings in Non-Current Deffered Revenue: grew 6.93% in 2016 and later plummeted 75.44% in 2017.
  • Year by year, Non-Current Deffered Revenue stood at $31239.0 in 2015, then plummeted by 47.8% to $16307.0 in 2016, then tumbled by 62.87% to $6054.0 in 2017, then surged by 98.22% to $12000.0 in 2018.
  • Business Quant data shows Non-Current Deffered Revenue for VKTX at $12000.0 in Q4 2018, $6054.0 in Q2 2017, and $10862.0 in Q1 2017.